Covaxin Vaccine

Bharat Biotech seeks approval for Covaxin in US for children below 18 years

Clinical trials were conducted on 526 kids during which no serious adverse events or hospitalisations were observed

Bharat Biotech's COVAXIN has 77.8% efficacy in Phase 3 trials, says report: All you need to know

The data will be reviewed by the WHO on 23 June in a 'pre-submission meeting', and COVAXIN will be allowed for export to other countries only after an approval from the global health body

Bharat Biotech expects peer review of Covaxin's Phase 3 trial data in Q4 2021

Raches Ella, project lead COVID-19 Vaccines at Bharat Biotech said that there were nine publications on Covaxin so far and the efficacy paper on Phase-3 trials would be the tenth one

Joe Biden announces COVID-19 vaccine sharing plan: US to send 25 million jabs around world

The White House said around 19 million will go to UN-backed program COVAX, with approximately 6 million for South and Central America, 7 million for Asia and 5 million for Africa

Increase gap between Covishield vaccine doses to 4-8 weeks, Centre tells states

This decision to revise the interval between doses from 4-6 weeks is applicable only to Covishield and not to Covaxin, the Union health ministry said

Covaxin phase 2 data shows vaccine safe, induces immune response, says Lancet study

The authors of the study noted that the phase 2 results did not assess the efficacy of the vaccine codenamed BBV152

Covaxin jab effective against UK variant of coronavirus, claims study

Covaxin - vaccine developed by Hyderabad-based Bharat Biotech - is effective against UK variants of COVID-19, according to a study on 26 participants, shared by the company on Wednesday.